News

(READ) Medicare won’t pay for controversial Alzheimer’s drug except for patients in studies

Medicare will only pay for patients to take a controversial new Alzheimer’s drug if they are enrolled in an approved study. That policy decision from the federal government is the latest blow to aducanumab, being sold by Biogen under the […]

(READ) Medicare won’t pay for controversial Alzheimer’s drug except for patients in studies Read More »

(READ) Watchdog group obtains documents on potential SEC crypto conflicts

The following is a public statement released by Empower Oversight. Empower Oversight received just under 200 pages of emails from the U.S. Securities and Exchange Commission (SEC) responsive to its FOIA request for records that could shed light on allegations of conflicts of interest associated with the

(READ) Watchdog group obtains documents on potential SEC crypto conflicts Read More »

Scroll to Top